ONCY / Oncolytics Biotech Inc. - SEC-arkiveringar, Årsredovisning, Fullmaktsutlåtande

Oncolytics Biotech® Announces Appointment of Steve Glover to Board of Directors and Promotion of John McAdory to Chief Operating Officer

Oncolytics Biotech® Announces Appointment of Steve Glover to Board of Directors and Promotion of John McAdory to Chief Operating Officer SAN DIEGO, CA, June 2, 2026 – Oncolytics Biotech® Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2026 Oncolytics Biotech I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2026 Oncolytics Biotech Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 001-38512 (Commission File Number) 98

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2026 Oncolytics Biotech I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2026 Oncolytics Biotech Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 001-38512 (Commission File Number) 98

Oncolytics Biotech® Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches Early results from solid tumor model support additional studies in pancreatic and colorectal c

Oncolytics Biotech® Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches Early results from solid tumor model support additional studies in pancreatic and colorectal cancer models; full dataset planned for presentation later in 2026 SAN DIEGO, CA, June 1, 2026 – Oncolytics Biotech® Inc.

Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep’s Potential Across Gastrointestinal Tumors Translational data demonstrate induction of both innate and adaptive antiviral and anti-tumor specific immune responses capable of cont

Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep’s Potential Across Gastrointestinal Tumors Translational data demonstrate induction of both innate and adaptive antiviral and anti-tumor specific immune responses capable of controlling tumor growth SAN DIEGO, CA, May 22, 2026 – Oncolytics Biotech® Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2026 Oncolytics Biotech I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2026 Oncolytics Biotech Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 001-38512 (Commission File Number) 98

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO . Commission file number: 001-38512 ONCOLYT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2026 Oncolytics Biotech In

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2026 Oncolytics Biotech Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 001-38512 (Commission File Number) 98-

Oncolytics Biotech® Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer 2L KRAS-Mutant MSS mCRC Demonstrates ~3–4x Improvement in Duration of Response vs. Historical 4–6 Month Benchmark Company Engaged with FDA to Support Potent

Oncolytics Biotech® Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer 2L KRAS-Mutant MSS mCRC Demonstrates ~3–4x Improvement in Duration of Response vs.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2026 Oncolytics Biotech

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2026 Oncolytics Biotech Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) 001-38512 (Commission File Number)

Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study Company to leverage strong durability and survival data in second-line and later metastatic squamous cell anal carcinoma Pivotal study expected to focus on patients in a post-standard-of

Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study Company to leverage strong durability and survival data in second-line and later metastatic squamous cell anal carcinoma Pivotal study expected to focus on patients in a post-standard-of-care patient population with no FDA-approved therapies SAN DIEGO, CA, April 27, 2026 – Oncolytics Biotech® Inc.

Oncolytics Biotech Inc. 4350 Executive Drive, Suite 325 San Diego, California 92121

Oncolytics Biotech Inc. 4350 Executive Drive, Suite 325 San Diego, California 92121 April 8, 2026 Via EDGAR Office of International Corporate Finance Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Oncolytics Biotech Inc. Withdrawal of Post-Effective Amendments to Registration Statements on Form F-10 To Whom It May Concern: Purs

Oncolytics Biotech Inc. 4350 Executive Drive, Suite 325 San Diego, California 92121

Oncolytics Biotech Inc. 4350 Executive Drive, Suite 325 San Diego, California 92121 April 8, 2026 Via EDGAR Office of International Corporate Finance Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Oncolytics Biotech Inc. Withdrawal of Post-Effective Amendments to Registration Statements on Form F-10 To Whom It May Concern: Purs

Oncolytics Biotech Inc. 4350 Executive Drive, Suite 325 San Diego, California 92121

Oncolytics Biotech Inc. 4350 Executive Drive, Suite 325 San Diego, California 92121 April 8, 2026 Via EDGAR Office of International Corporate Finance Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Oncolytics Biotech Inc. Withdrawal of Post-Effective Amendments to Registration Statements on Form F-10 To Whom It May Concern: Purs

Oncolytics Biotech Inc. 4350 Executive Drive, Suite 325 San Diego, California 92121

Oncolytics Biotech Inc. 4350 Executive Drive, Suite 325 San Diego, California 92121 April 8, 2026 Via EDGAR Office of International Corporate Finance Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Oncolytics Biotech Inc. Withdrawal of Post-Effective Amendments to Registration Statements on Form F-10 To Whom It May Concern: Purs

As filed with the U.S. Securities and Exchange Commission on April 8, 2026.

As filed with the U.S. Securities and Exchange Commission on April 8, 2026. Registration Statement No. 333-140460 Registration Statement No. 333-140529 Registration Statement No. 333-151513 Registration Statement No. 333-167250 Registration Statement No. 333-182260 Registration Statement No. 333-197633 Registration Statement No. 333-224432 Registration Statement No. 333-239025 Registration Stateme

Oncolytics Biotech Inc. 4350 Executive Drive, Suite 325 San Diego, California 92121

Oncolytics Biotech Inc. 4350 Executive Drive, Suite 325 San Diego, California 92121 April 8, 2026 Via EDGAR Office of International Corporate Finance Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Oncolytics Biotech Inc. Withdrawal of Post-Effective Amendments to Registration Statements on Form F-10 To Whom It May Concern: Purs

As filed with the U.S. Securities and Exchange Commission on April 8, 2026.

As filed with the U.S. Securities and Exchange Commission on April 8, 2026. Registration Statement No. 333-140460 Registration Statement No. 333-140529 Registration Statement No. 333-151513 Registration Statement No. 333-167250 Registration Statement No. 333-182260 Registration Statement No. 333-197633 Registration Statement No. 333-224432 Registration Statement No. 333-239025 Registration Stateme

As filed with the U.S. Securities and Exchange Commission on April 8, 2026.

As filed with the U.S. Securities and Exchange Commission on April 8, 2026. Registration Statement No. 333-140460 Registration Statement No. 333-140529 Registration Statement No. 333-151513 Registration Statement No. 333-167250 Registration Statement No. 333-182260 Registration Statement No. 333-197633 Registration Statement No. 333-224432 Registration Statement No. 333-239025 Registration Stateme

As filed with the U.S. Securities and Exchange Commission on April 8, 2026.

As filed with the U.S. Securities and Exchange Commission on April 8, 2026. Registration Statement No. 333-140460 Registration Statement No. 333-140529 Registration Statement No. 333-151513 Registration Statement No. 333-167250 Registration Statement No. 333-182260 Registration Statement No. 333-197633 Registration Statement No. 333-224432 Registration Statement No. 333-239025 Registration Stateme

As filed with the U.S. Securities and Exchange Commission on April 8, 2026.

As filed with the U.S. Securities and Exchange Commission on April 8, 2026. Registration Statement No. 333-140460 Registration Statement No. 333-140529 Registration Statement No. 333-151513 Registration Statement No. 333-167250 Registration Statement No. 333-182260 Registration Statement No. 333-197633 Registration Statement No. 333-224432 Registration Statement No. 333-239025 Registration Stateme

Oncolytics Biotech Inc. 4350 Executive Drive, Suite 325 San Diego, California 92121

Oncolytics Biotech Inc. 4350 Executive Drive, Suite 325 San Diego, California 92121 April 8, 2026 Via EDGAR Office of International Corporate Finance Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Oncolytics Biotech Inc. Withdrawal of Post-Effective Amendments to Registration Statements on Form F-10 To Whom It May Concern: Purs

Oncolytics Biotech Inc. 4350 Executive Drive, Suite 325 San Diego, California 92121

Oncolytics Biotech Inc. 4350 Executive Drive, Suite 325 San Diego, California 92121 April 8, 2026 Via EDGAR Office of International Corporate Finance Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Oncolytics Biotech Inc. Withdrawal of Post-Effective Amendments to Registration Statements on Form F-10 To Whom It May Concern: Purs

Oncolytics Biotech Inc. 4350 Executive Drive, Suite 325 San Diego, California 92121

Oncolytics Biotech Inc. 4350 Executive Drive, Suite 325 San Diego, California 92121 April 8, 2026 Via EDGAR Office of International Corporate Finance Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Oncolytics Biotech Inc. Withdrawal of Post-Effective Amendments to Registration Statements on Form F-10 To Whom It May Concern: Purs

Oncolytics Biotech Inc. 4350 Executive Drive, Suite 325 San Diego, California 92121

Oncolytics Biotech Inc. 4350 Executive Drive, Suite 325 San Diego, California 92121 April 8, 2026 Via EDGAR Office of International Corporate Finance Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Oncolytics Biotech Inc. Withdrawal of Post-Effective Amendments to Registration Statements on Form F-10 To Whom It May Concern: Purs

Oncolytics Biotech Inc. 4350 Executive Drive, Suite 325 San Diego, California 92121

Oncolytics Biotech Inc. 4350 Executive Drive, Suite 325 San Diego, California 92121 April 8, 2026 Via EDGAR Office of International Corporate Finance Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Oncolytics Biotech Inc. Withdrawal of Post-Effective Amendments to Registration Statements on Form F-10 To Whom It May Concern: Purs

As filed with the U.S. Securities and Exchange Commission on April 8, 2026.

As filed with the U.S. Securities and Exchange Commission on April 8, 2026. Registration Statement No. 333-140460 Registration Statement No. 333-140529 Registration Statement No. 333-151513 Registration Statement No. 333-167250 Registration Statement No. 333-182260 Registration Statement No. 333-197633 Registration Statement No. 333-224432 Registration Statement No. 333-239025 Registration Stateme

As filed with the U.S. Securities and Exchange Commission on April 8, 2026.

As filed with the U.S. Securities and Exchange Commission on April 8, 2026. Registration Statement No. 333-140460 Registration Statement No. 333-140529 Registration Statement No. 333-151513 Registration Statement No. 333-167250 Registration Statement No. 333-182260 Registration Statement No. 333-197633 Registration Statement No. 333-224432 Registration Statement No. 333-239025 Registration Stateme

As filed with the U.S. Securities and Exchange Commission on April 8, 2026.

As filed with the U.S. Securities and Exchange Commission on April 8, 2026. Registration Statement No. 333-140460 Registration Statement No. 333-140529 Registration Statement No. 333-151513 Registration Statement No. 333-167250 Registration Statement No. 333-182260 Registration Statement No. 333-197633 Registration Statement No. 333-224432 Registration Statement No. 333-239025 Registration Stateme

As filed with the U.S. Securities and Exchange Commission on April 8, 2026.

As filed with the U.S. Securities and Exchange Commission on April 8, 2026. Registration Statement No. 333-140460 Registration Statement No. 333-140529 Registration Statement No. 333-151513 Registration Statement No. 333-167250 Registration Statement No. 333-182260 Registration Statement No. 333-197633 Registration Statement No. 333-224432 Registration Statement No. 333-239025 Registration Stateme

As filed with the U.S. Securities and Exchange Commission on April 8, 2026.

As filed with the U.S. Securities and Exchange Commission on April 8, 2026. Registration Statement No. 333-140460 Registration Statement No. 333-140529 Registration Statement No. 333-151513 Registration Statement No. 333-167250 Registration Statement No. 333-182260 Registration Statement No. 333-197633 Registration Statement No. 333-224432 Registration Statement No. 333-239025 Registration Stateme

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 6, 2026 Oncolytics Biotech

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 6, 2026 Oncolytics Biotech Inc. (Exact name of registrant as specified in its charter) Alberta, Canada (State or other jurisdiction of incorporation) 001-38512 (Commission File

$75,000,000 Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-294811 PROSPECTUS SUPPLEMENT (to Prospectus dated April 3, 2026) $75,000,000 Common Stock We have entered into an Open Market Sale AgreementSM (the “Sales Agreement”) with Jefferies LLC (“Jefferies”) relating to shares of our common stock, par value $0.001 per share, offered by this prospectus supplement and the accompanying prospectus. In acco

As filed with the U.S. Securities and Exchange Commission on April 6, 2026.

As filed with the U.S. Securities and Exchange Commission on April 6, 2026. Registration Statement No. 333-140460 Registration Statement No. 333-140529 Registration Statement No. 333-151513 Registration Statement No. 333-167250 Registration Statement No. 333-182260 Registration Statement No. 333-197633 Registration Statement No. 333-224432 Registration Statement No. 333-239025 Registration Stateme

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 6, 2026 Oncolytics Biotech

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 6, 2026 Oncolytics Biotech Inc. (Exact name of registrant as specified in its charter) Nevada 001-38512 98-0541667 (State or other jurisdiction of incorporation) (Commission Fil

OPEN MARKET SALE AGREEMENTSM

Exhibit 1.1 OPEN MARKET SALE AGREEMENTSM April 6, 2026 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Oncolytics Biotech Inc., a Nevada corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stoc

As filed with the U.S. Securities and Exchange Commission on April 6, 2026.

As filed with the U.S. Securities and Exchange Commission on April 6, 2026. Registration Statement No. 333-140460 Registration Statement No. 333-140529 Registration Statement No. 333-151513 Registration Statement No. 333-167250 Registration Statement No. 333-182260 Registration Statement No. 333-197633 Registration Statement No. 333-224432 Registration Statement No. 333-239025 Registration Stateme

As filed with the U.S. Securities and Exchange Commission on April 6, 2026.

As filed with the U.S. Securities and Exchange Commission on April 6, 2026. Registration Statement No. 333-140460 Registration Statement No. 333-140529 Registration Statement No. 333-151513 Registration Statement No. 333-167250 Registration Statement No. 333-182260 Registration Statement No. 333-197633 Registration Statement No. 333-224432 Registration Statement No. 333-239025 Registration Stateme

As filed with the U.S. Securities and Exchange Commission on April 6, 2026.

As filed with the U.S. Securities and Exchange Commission on April 6, 2026. Registration Statement No. 333-140460 Registration Statement No. 333-140529 Registration Statement No. 333-151513 Registration Statement No. 333-167250 Registration Statement No. 333-182260 Registration Statement No. 333-197633 Registration Statement No. 333-224432 Registration Statement No. 333-239025 Registration Stateme

As filed with the U.S. Securities and Exchange Commission on April 6, 2026.

As filed with the U.S. Securities and Exchange Commission on April 6, 2026. Registration Statement No. 333-140460 Registration Statement No. 333-140529 Registration Statement No. 333-151513 Registration Statement No. 333-167250 Registration Statement No. 333-182260 Registration Statement No. 333-197633 Registration Statement No. 333-224432 Registration Statement No. 333-239025 Registration Stateme

As filed with the U.S. Securities and Exchange Commission on April 6, 2026.

As filed with the U.S. Securities and Exchange Commission on April 6, 2026. Registration Statement No. 333-140460 Registration Statement No. 333-140529 Registration Statement No. 333-151513 Registration Statement No. 333-167250 Registration Statement No. 333-182260 Registration Statement No. 333-197633 Registration Statement No. 333-224432 Registration Statement No. 333-239025 Registration Stateme

As filed with the U.S. Securities and Exchange Commission on April 6, 2026.

As filed with the U.S. Securities and Exchange Commission on April 6, 2026. Registration Statement No. 333-140460 Registration Statement No. 333-140529 Registration Statement No. 333-151513 Registration Statement No. 333-167250 Registration Statement No. 333-182260 Registration Statement No. 333-197633 Registration Statement No. 333-224432 Registration Statement No. 333-239025 Registration Stateme

Oncolytics Biotech® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer

Oncolytics Biotech® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer SAN DIEGO, CA, April 6, 2026 – Oncolytics Biotech® Inc.

As filed with the U.S. Securities and Exchange Commission on April 6, 2026.

As filed with the U.S. Securities and Exchange Commission on April 6, 2026. Registration Statement No. 333-140460 Registration Statement No. 333-140529 Registration Statement No. 333-151513 Registration Statement No. 333-167250 Registration Statement No. 333-182260 Registration Statement No. 333-197633 Registration Statement No. 333-224432 Registration Statement No. 333-239025 Registration Stateme

As filed with the U.S. Securities and Exchange Commission on April 6, 2026.

As filed with the U.S. Securities and Exchange Commission on April 6, 2026. Registration Statement No. 333-140460 Registration Statement No. 333-140529 Registration Statement No. 333-151513 Registration Statement No. 333-167250 Registration Statement No. 333-182260 Registration Statement No. 333-197633 Registration Statement No. 333-224432 Registration Statement No. 333-239025 Registration Stateme

As filed with the U.S. Securities and Exchange Commission on April 6, 2026.

As filed with the U.S. Securities and Exchange Commission on April 6, 2026. Registration Statement No. 333-140460 Registration Statement No. 333-140529 Registration Statement No. 333-151513 Registration Statement No. 333-167250 Registration Statement No. 333-182260 Registration Statement No. 333-197633 Registration Statement No. 333-224432 Registration Statement No. 333-239025 Registration Stateme

LETTER

April 1, 2026 Jared Kelly Chief Executive Officer Oncolytics Biotech Inc. 4350 Executive Drive, Suite 325 San Diego, California 92121 Re: Oncolytics Biotech Inc. Registration Statement on Form S-3 Filed April 1, 2026 File No. 333-294811 Dear Jared Kelly: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requ

As filed with the U.S. Securities and Exchange Commission on March 31, 2026.

As filed with the U.S. Securities and Exchange Commission on March 31, 2026. Registration Statement No. 333-140460 Registration Statement No. 333-140529 Registration Statement No. 333-151513 Registration Statement No. 333-167250 Registration Statement No. 333-182260 Registration Statement No. 333-197633 Registration Statement No. 333-224432 Registration Statement No. 333-239025 Registration Statem

As filed with the U.S. Securities and Exchange Commission on March 31, 2026.

As filed with the U.S. Securities and Exchange Commission on March 31, 2026. Registration Statement No. 333-140460 Registration Statement No. 333-140529 Registration Statement No. 333-151513 Registration Statement No. 333-167250 Registration Statement No. 333-182260 Registration Statement No. 333-197633 Registration Statement No. 333-224432 Registration Statement No. 333-239025 Registration Statem

As filed with the U.S. Securities and Exchange Commission on March 31, 2026.

As filed with the U.S. Securities and Exchange Commission on March 31, 2026. Registration Statement No. 333-140460 Registration Statement No. 333-140529 Registration Statement No. 333-151513 Registration Statement No. 333-167250 Registration Statement No. 333-182260 Registration Statement No. 333-197633 Registration Statement No. 333-224432 Registration Statement No. 333-239025 Registration Statem

Exhibit 3.1

Exhibit 3.1

  ARTICLES OF INCORPORATION OF ONCOLYTICS BIOTECH INC. ARTICLE I name

  Exhibit 4.2   ARTICLES OF INCORPORATION OF ONCOLYTICS BIOTECH INC.   ARTICLE I name   The name of the Corporation is Oncolytics Biotech Inc. (the “Corporation”).   ARTICLE II registered office and registered agent   The registered office of the Corporation shall be the street address of its registered agent in the State of Nevada. The Corporation may, from time to time, in the manner provided by

Exhibit 4.1

Exhibit 4.1

As filed with the U.S. Securities and Exchange Commission on March 31, 2026.

As filed with the U.S. Securities and Exchange Commission on March 31, 2026. Registration Statement No. 333-140460 Registration Statement No. 333-140529 Registration Statement No. 333-151513 Registration Statement No. 333-167250 Registration Statement No. 333-182260 Registration Statement No. 333-197633 Registration Statement No. 333-224432 Registration Statement No. 333-239025 Registration Statem

As filed with the U.S. Securities and Exchange Commission on March 31, 2026.

As filed with the U.S. Securities and Exchange Commission on March 31, 2026. Registration Statement No. 333-140460 Registration Statement No. 333-140529 Registration Statement No. 333-151513 Registration Statement No. 333-167250 Registration Statement No. 333-182260 Registration Statement No. 333-197633 Registration Statement No. 333-224432 Registration Statement No. 333-239025 Registration Statem

  ARTICLES OF INCORPORATION OF ONCOLYTICS BIOTECH INC. ARTICLE I name

  Exhibit 3.2   ARTICLES OF INCORPORATION OF ONCOLYTICS BIOTECH INC.   ARTICLE I name   The name of the Corporation is Oncolytics Biotech Inc. (the “Corporation”).   ARTICLE II registered office and registered agent   The registered office of the Corporation shall be the street address of its registered agent in the State of Nevada. The Corporation may, from time to time, in the manner provided by

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2026 Oncolytics Biotech

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2026 Oncolytics Biotech Inc. (Exact name of registrant as specified in its charter) Nevada 001-38512 98-0541667 (State or other jurisdiction of incorporation) (Commission Fi

  ONCOLYTICS BIOTECH INC. a Nevada corporation Article I OFFICES

  Exhibit 4.3   BYLAWS of ONCOLYTICS BIOTECH INC. a Nevada corporation   Article I OFFICES   Section 1.1               Principal Office. The principal office and place of business of Oncolytics Biotech Inc. (the “Corporation”) shall be at such location as is established from time to time by resolution of the board of directors of the Corporation (the “Board of Directors”).   Section 1.2           

As filed with the U.S. Securities and Exchange Commission on March 31, 2026.

As filed with the U.S. Securities and Exchange Commission on March 31, 2026. Registration No. 333-289819 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Oncolytics Biotech Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorp

As filed with the Securities and Exchange Commission on March 31, 2026

As filed with the Securities and Exchange Commission on March 31, 2026 Registration No.

Oncolytics Biotech® Completes Domicile Change to the United States

Exhibit 99.2 Oncolytics Biotech® Completes Domicile Change to the United States SAN DIEGO, CA, April 1, 2026 – Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced the completion of the previously announced change in the jurisdiction of incorporation of Oncolytics from the Province of Alberta in Canad

As filed with the U.S. Securities and Exchange Commission on March 31, 2026.

As filed with the U.S. Securities and Exchange Commission on March 31, 2026. Registration Statement No. 333-140460 Registration Statement No. 333-140529 Registration Statement No. 333-151513 Registration Statement No. 333-167250 Registration Statement No. 333-182260 Registration Statement No. 333-197633 Registration Statement No. 333-224432 Registration Statement No. 333-239025 Registration Statem

As filed with the U.S. Securities and Exchange Commission on March 31, 2026.

As filed with the U.S. Securities and Exchange Commission on March 31, 2026. Registration No. 333-171625 Registration No. 333-205708 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT (333-171625) POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT (333-205708) UNDER THE SECURITIES ACT OF 1933 Onco

  ONCOLYTICS BIOTECH INC. a Nevada corporation Article I OFFICES

  Exhibit 3.3   BYLAWS of ONCOLYTICS BIOTECH INC. a Nevada corporation   Article I OFFICES   Section 1.1               Principal Office. The principal office and place of business of Oncolytics Biotech Inc. (the “Corporation”) shall be at such location as is established from time to time by resolution of the board of directors of the Corporation (the “Board of Directors”).   Section 1.2           

ONCOLYTICS BIOTECH INC. 2026 Incentive Award Plan

Exhibit 99.1 ONCOLYTICS BIOTECH INC. 2026 Incentive Award Plan ARTICLE I. Purpose The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing these individuals with equity ownership opportunities and/or equity-linked compensatory opportunities. Capitalized terms used in the Pla

As filed with the U.S. Securities and Exchange Commission on March 31, 2026.

As filed with the U.S. Securities and Exchange Commission on March 31, 2026. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Oncolytics Biotech Inc. (Exact name of registrant as specified in its charter) Nevada 98-0541667 (State or other jurisdiction of incorporation or organization) (I.R

As filed with the U.S. Securities and Exchange Commission on March 31, 2026.

As filed with the U.S. Securities and Exchange Commission on March 31, 2026. Registration Statement No. 333-140460 Registration Statement No. 333-140529 Registration Statement No. 333-151513 Registration Statement No. 333-167250 Registration Statement No. 333-182260 Registration Statement No. 333-197633 Registration Statement No. 333-224432 Registration Statement No. 333-239025 Registration Statem

ONCOLYTICS BIOTECH INC. 4350 Executive Drive, Suite 325 San Diego, California 92121

ONCOLYTICS BIOTECH INC. 4350 Executive Drive, Suite 325 San Diego, California 92121 VIA EDGAR April 1, 2026 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Tim Buchmiller Re: Oncolytics Biotech Inc. Registration Statement on Form S-3 Filed April 1, 2026 File No. 333-294811 To the addressee

Table 1: Newly Registered Securities

Calculation of Filing Fee Tables S-8 ONCOLYTICS BIOTECH INC Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, $0.

As filed with the U.S. Securities and Exchange Commission on March 31, 2026.

As filed with the U.S. Securities and Exchange Commission on March 31, 2026. Registration No. 333-171625 Registration No. 333-205708 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT (333-171625) POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT (333-205708) UNDER THE SECURITIES ACT OF 1933 Onco

As filed with the U.S. Securities and Exchange Commission on March 31, 2026.

As filed with the U.S. Securities and Exchange Commission on March 31, 2026. Registration Statement No. 333-140460 Registration Statement No. 333-140529 Registration Statement No. 333-151513 Registration Statement No. 333-167250 Registration Statement No. 333-182260 Registration Statement No. 333-197633 Registration Statement No. 333-224432 Registration Statement No. 333-239025 Registration Statem

Exhibit 3.1

Exhibit 3.1

Security Type

Calculation of Filing Fee Tables S-3 ONCOLYTICS BIOTECH INC Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Newly Registered Securities Equity Common Stock 457(o) Equity Preferred Stock 457(o) Other Warrants 457(o) Other Purchase Contracts 457(o) Other Units 457(o) Fees to be Paid 1 Unallocated (Universal) Shelf 457(o) $ 110,997,614.

As filed with the U.S. Securities and Exchange Commission on March 31, 2026.

As filed with the U.S. Securities and Exchange Commission on March 31, 2026. Registration Statement No. 333-140460 Registration Statement No. 333-140529 Registration Statement No. 333-151513 Registration Statement No. 333-167250 Registration Statement No. 333-182260 Registration Statement No. 333-197633 Registration Statement No. 333-224432 Registration Statement No. 333-239025 Registration Statem

As filed with the U.S. Securities and Exchange Commission on March 31, 2026.

As filed with the U.S. Securities and Exchange Commission on March 31, 2026. Registration Statement No. 333-140460 Registration Statement No. 333-140529 Registration Statement No. 333-151513 Registration Statement No. 333-167250 Registration Statement No. 333-182260 Registration Statement No. 333-197633 Registration Statement No. 333-224432 Registration Statement No. 333-239025 Registration Statem

INDUCEMENT PERFORMANCE RESTRICTED SHARE AWARD AGREEMENT SUBJECT TO THE ONCOLYTICS BIOTECH INC. INCENTIVE SHARE AWARD PLAN

EXHIBIT 10.11 INDUCEMENT PERFORMANCE RESTRICTED SHARE AWARD AGREEMENT SUBJECT TO THE ONCOLYTICS BIOTECH INC. INCENTIVE SHARE AWARD PLAN Participant: [Name] Grant Date: [Date] Number of Performance RSUs: [Number] THIS INDUCEMENT PERFORMANCE RESTRICTED SHARE AWARD AGREEMENT (this “Agreement”), dated as of the Grant Date specified above, is entered into by and between Oncolytics Biotech Inc. (the “Co

INDUCEMENT NON-QUALIFIED STOCK OPTION AGREEMENT SUBJECT TO THE ONCOLYTICS BIOTECH INC. STOCK OPTION PLAN

EXHIBIT 10.10 INDUCEMENT NON-QUALIFIED STOCK OPTION AGREEMENT SUBJECT TO THE ONCOLYTICS BIOTECH INC. STOCK OPTION PLAN Participant: [Name] Grant Date: [Date] Per Share Exercise Price: [$] Number of Option Shares: [Number] THIS INDUCEMENT NON-QUALIFIED STOCK OPTION AWARD AGREEMENT (this “Agreement”), dated as of the Grant Date specified above, is entered into by and between Oncolytics Biotech Inc.

SUBSIDIARIES OF ONCOLYTICS BIOTECH INC.

EXHIBIT 21.1 SUBSIDIARIES OF ONCOLYTICS BIOTECH INC. Name Jurisdiction Oncolytics Biotech (Barbados) Inc. Barbados Oncolytics Biotech (US) Inc. Delaware Oncolytics Biotech (Canada) Inc. Canada

RESTRICTED SHARE AWARD AGREEMENT

EXHIBIT 10.9 RESTRICTED SHARE AWARD AGREEMENT THIS AGREEMENT made as of BETWEEN: ONCOLYTICS BIOTECH INC., a Company amalgamated under the laws of the Province of Alberta (hereinafter called the “Company”) OF THE FIRST PART - and - (hereinafter called the “Participant”) OF THE SECOND PART WHEREAS the Company is authorized to issue an unlimited number of common shares (“Common Shares”); AND WHEREAS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO . Commission file number: 001-38512 ONCOLYTICS B

INDUCEMENT PERFORMANCE RESTRICTED SHARE AWARD AGREEMENT SUBJECT TO THE ONCOLYTICS BIOTECH INC. INCENTIVE SHARE AWARD PLAN

EXHIBIT 10.13 INDUCEMENT PERFORMANCE RESTRICTED SHARE AWARD AGREEMENT SUBJECT TO THE ONCOLYTICS BIOTECH INC. INCENTIVE SHARE AWARD PLAN Participant: Jared Kelly Grant Date: June 10, 2025 Number of Performance RSUS: 1,886,340 THIS INDUCEMENT PERFORMANCE RESTRICTED SHARE AWARD AGREEMENT (this “Agreement”), dated as of the Grant Date specified above, is entered into by and between Oncolytics Biotech

INDUCEMENT NON-QUALIFIED STOCK OPTION AGREEMENT SUBJECT TO THE ONCOLYTICS BIOTECH INC. STOCK OPTION PLAN

EXHIBIT 10.12 INDUCEMENT NON-QUALIFIED STOCK OPTION AGREEMENT SUBJECT TO THE ONCOLYTICS BIOTECH INC. STOCK OPTION PLAN Participant: Jared Kelly Grant Date: June 10, 2025 Per Share Exercise Price: CAD $0.57 Number of Option Shares: 4,750,000 THIS INDUCEMENT NON-QUALIFIED STOCK OPTION AWARD AGREEMENT (this “Agreement”), dated as of the Grant Date specified above, is entered into by and between Oncol

OPTION AGREEMENT

EXHIBIT 10.8 OPTION AGREEMENT THIS AGREEMENT made as of BETWEEN: ONCOLYTICS BIOTECH INC., a Company amalgamated under the laws of the Province of Alberta (hereinafter called the “Company”) OF THE FIRST PART - and - (hereinafter called the “Participant”) OF THE SECOND PART WHEREAS the Company is authorized to issue an unlimited number of common shares (“Common Shares”); AND WHEREAS the Company may

DESCRIPTION OF CAPITAL STOCK

Exhibit 4.1 DESCRIPTION OF CAPITAL STOCK The following description sets forth certain material terms and provisions of the securities of Oncolytics Biotech Inc. (“we,” “us” or “our”) that are registered under Section 12 of the U.S. Securities Exchange Act of 1934, as amended. The following description of our securities is not complete and may not contain all the information you should consider bef

INDEMNIFICATION AND ADVANCEMENT AGREEMENT

EXHIBIT 10.15 INDEMNIFICATION AND ADVANCEMENT AGREEMENT FORM This Indemnification and Advancement Agreement (this “Agreement”) is made as of , 20 by and between Oncolytics Biotech Inc., a Nevada corporation (the “Company”), and , a member of the Board of Directors/an officer/an employee of the Company (“Indemnitee”). This Agreement supersedes and replaces any and all previous Agreements between th

Oncolytics Biotech Inc. PROVINCE OF BRITISH COLUMBIA BUSINESS CORPORATIONS ACT TABLE OF CONTENTS

Exhibit 3.3 Incorporation Number C1582211 Effective as of March 17, 2026 ARTICLES OF Oncolytics Biotech Inc. PROVINCE OF BRITISH COLUMBIA BUSINESS CORPORATIONS ACT TABLE OF CONTENTS Article 1 INTERPRETATION Section 1.1 Definitions 1 Section 1.2 BCA and Interpretation Act Definitions Applicable 2 Section 1.3 Conflicts or Inconsistencies 2 Article 2 SHARES AND SHARE CERTIFICATES Section 2.1 Authoriz

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2026 Oncolytics Biotech

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2026 Oncolytics Biotech Inc. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-38512 98-0541667 (State or other jurisdiction of incorporati

NOTICE OF ARTICLES

Exhibit 3.2 Mailing Address: Location: PO Box 9431 Stn Prov Govt 2nd Floor - 940 Blanshard Street Victoria BC V8W 9V3 Victoria BC www.corporateonline.gov.bc.ca 1 877 526-1526 CERTIFIED COPY Of a Document filed with the Province of British Columbia Registrar of Companies Notice of Articles /s/ Kerry Taylor BUSINESS CORPORATIONS ACT KERRY TAYLOR This Notice of Articles was issued by the Registrar on

CERTIFICATE BUSINESS CORPORATIONS ACT

Exhibit 3.1 Number: C1582211 CERTIFICATE OF CONTINUATION BUSINESS CORPORATIONS ACT I Hereby Certify that Oncolytics Biotech Inc., has continued into British Columbia from the Jurisdiction of ALBERTA, under the Business Corporations Act, with the name ONCOLYTICS BIOTECH INC. on March 17, 2026 at 09:01 AM Pacific Time. Issued under my hand at Victoria, British Columbia On March 17, 2026 /s/ Kerry Ta

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2026 Oncolytics Biotech

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2026 Oncolytics Biotech Inc. (Exact name of registrant as specified in its charter) Alberta, Canada (State or other jurisdiction of incorporation) 001-38512 (Commission File

Oncolytics Biotech® to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026 Pelareorep treatment drives coordinated immune activation and tertiary lymphoid structure formation Translational d

Oncolytics Biotech® to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026 Pelareorep treatment drives coordinated immune activation and tertiary lymphoid structure formation Translational data suggest potential to boost response to immunotherapy and targeted therapy in RAS-driven tumors Pelareorep’s ability to engage the innate and adaptive immune system results in doubling or nearly tripling response rates in breast and gastrointestinal cancers SAN DIEGO, CA, March 19, 2026 – Oncolytics Biotech® Inc.

Oncolytics Biotech® Launches Randomized Colorectal Cancer Study Controlled study designed to confirm previous compelling efficacy with preliminary data expected by the end of 2026 Pelareorep-based treatment regimen recently granted Fast Track Designa

Oncolytics Biotech® Launches Randomized Colorectal Cancer Study Controlled study designed to confirm previous compelling efficacy with preliminary data expected by the end of 2026 Pelareorep-based treatment regimen recently granted Fast Track Designation in 2L KRAS-mutant MSS metastatic colorectal cancer, confirming its potential in this large indication SAN DIEGO, CA, March 2, 2026 – Oncolytics Biotech® Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2026 Oncolytics Biotech

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2026 Oncolytics Biotech Inc. (Exact name of registrant as specified in its charter) Alberta, Canada (State or other jurisdiction of incorporation) 001-38512 (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2026 Oncolytics Biot

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2026 Oncolytics Biotech Inc. (Exact name of registrant as specified in its charter) Alberta, Canada (State or other jurisdiction of incorporation) 001-38512 (Commission F

Oncolytics Biotech® to Prioritize Registration-Focused Programs in Anal and Colorectal Cancer Company to wind down the GOBLET gastrointestinal study to focus on registration path in the U.S. With sufficient cash on hand to execute near-term milestone

Oncolytics Biotech® to Prioritize Registration-Focused Programs in Anal and Colorectal Cancer Company to wind down the GOBLET gastrointestinal study to focus on registration path in the U.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2026 Oncolytics Biote

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2026 Oncolytics Biotech Inc. (Exact name of registrant as specified in its charter) Alberta, Canada (State or other jurisdiction of incorporation) 001-38512 (Commission Fi

Oncolytics Biotech® Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer Strong efficacy signals showing 33% ORR, 16.6-month PFS, and 27-month OS, improving on the SOC by 2-3X in a difficult-to-treat p

Oncolytics Biotech® Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer Strong efficacy signals showing 33% ORR, 16.

Oncolytics Biotech® Announces Results of Special Meeting of Shareholders All resolutions passed, enabling the Company to streamline regulatory and operational processes

Exhibit 99.1 Oncolytics Biotech® Announces Results of Special Meeting of Shareholders All resolutions passed, enabling the Company to streamline regulatory and operational processes SAN DIEGO, CA, January 15, 2026 – Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced the voting results from its Speci

Oncolytics Biotech® Appoints John McAdory as EVP of Strategy and Operations and Yujun Wu to Lead Biostatistics Appointments strengthen late-stage clinical execution and statistical leadership as the Company advances multiple registration-directed pro

Exhibit 99.1 Oncolytics Biotech® Appoints John McAdory as EVP of Strategy and Operations and Yujun Wu to Lead Biostatistics Appointments strengthen late-stage clinical execution and statistical leadership as the Company advances multiple registration-directed programs in gastrointestinal cancers SAN DIEGO, CA, January 14, 2026 – Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 15, 2026 Oncolytics Biote

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 15, 2026 Oncolytics Biotech Inc. (Exact name of registrant as specified in its charter) Alberta, Canada 001-38512 26-3847449 (State or other jurisdiction of incorporation) (Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2026 Oncolytics Biote

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2026 Oncolytics Biotech, Inc. (Exact name of registrant as specified in its charter) Alberta, Canada 001-38512 26-3847449 (State or other jurisdiction of incorporation) (C

Oncolytics Biotech® Provides Update on Intellectual Property Strategy and Patent Filings Track 1 manufacturing patent application and additional planned filings to potentially extend patent coverage beyond 2044

Exhibit 99.1 Oncolytics Biotech® Provides Update on Intellectual Property Strategy and Patent Filings Track 1 manufacturing patent application and additional planned filings to potentially extend patent coverage beyond 2044 SAN DIEGO, CA, January 8, 2026 – Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today pr

Oncolytics Biotech® Announces Updated Clinical Data from GOBLET Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal Cancer Compared to the historical benchmark, pelareorep-atezolizumab nearly tripled ORR Combination ach

Exhibit 99.2 Oncolytics Biotech® Announces Updated Clinical Data from GOBLET Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal Cancer Compared to the historical benchmark, pelareorep-atezolizumab nearly tripled ORR Combination achieved encouraging median DOR of almost 17 months Data establishes clear path in indication with no approved therapy SAN DIEGO, CA, Januar

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2026 Oncolytics Biotec

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2026 Oncolytics Biotech, Inc. (Exact name of registrant as specified in its charter) Alberta, Canada 001-38512 26-3847449 (State or other jurisdiction of incorporation) (Co

Oncolytics Biotech® Outlines Strategic Rationale for Proposal to Change Jurisdiction of Incorporation to Nevada

Filed by Oncolytics Biotech Inc. Pursuant to Rule 425 under the U.S. Securities Act of 1933, as amended and deemed filed pursuant to Rule 14a-6(b) under the U.S. Securities Exchange Act of 1934, as amended Subject Company: Oncolytics Biotech Inc. Commission File No.: 333-290954 Oncolytics Biotech® Outlines Strategic Rationale for Proposal to Change Jurisdiction of Incorporation to Nevada SAN DIEGO

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January 2026 Commission File Number 001-38512 Oncolytics Bio

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January 2026 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) 4350 Executive Drive, Suite 325 San Diego, CA 92121 (Address of principal executive offices)

Oncolytics Biotech® Expands Its Gastrointestinal Tumor Scientific Advisory Board with the Addition of Dr. Eileen O’Reilly, Dr. Neil Segal, and Dr. Van Morris New members bring deep experience in pancreatic, colorectal, and anal cancers to guide pelar

Oncolytics Biotech® Expands Its Gastrointestinal Tumor Scientific Advisory Board with the Addition of Dr.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2025 Commission File Number 001-38512 Oncolytics Bi

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) 4350 Executive Drive, Suite 325 San Diego, CA 92121 (Address of principal executive offices

Oncolytics Biotech® Announces Promising Efficacy and Translational Data Supporting Pelareorep in KRAS-Mutant Metastatic Colorectal Cancer 33% ORR achieved in second-line KRAS-mutant MSS colorectal cancer—triple historical response rates for Avastin +

Oncolytics Biotech® Announces Promising Efficacy and Translational Data Supporting Pelareorep in KRAS-Mutant Metastatic Colorectal Cancer 33% ORR achieved in second-line KRAS-mutant MSS colorectal cancer—triple historical response rates for Avastin + FOLFIRI of 6-11% Translational analysis shows pelareorep enhances KRAS-mutant–specific T-cell activity, providing mechanistic support for clinical responses Data strengthen pelareorep’s potential to transform a multi–billion dollar underserved colorectal cancer market SAN DIEGO, CA, December 16, 2025 – Oncolytics Biotech® Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2025 Commission File Number 001-38512 Oncolytics Bi

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) 4350 Executive Drive, Suite 325 San Diego, CA 92121 (Address of principal executive offices

Oncolytics Biotech® Reschedules Special Meeting of Shareholders to Change Jurisdiction of Incorporation to Nevada

Oncolytics Biotech® Reschedules Special Meeting of Shareholders to Change Jurisdiction of Incorporation to Nevada SAN DIEGO, Dec.

Management Information Circular Oncolytics Biotech Inc. with respect to its Special Meeting of Shareholders Oncolytics Biotech Inc. AUTHORIZING THE CONTINUANCE, AUTHORIZING THE DOMESTICATION, AND APPROVAL OF 2026 INCENTIVE AWARD PLAN

Filed Pursuant to Rule 424(b)(3) Registration No. 333-290954 Management Information Circular of Oncolytics Biotech Inc. with respect to its Special Meeting of Shareholders and Prospectus of Oncolytics Biotech Inc. AUTHORIZING THE CONTINUANCE, AUTHORIZING THE DOMESTICATION, AND APPROVAL OF 2026 INCENTIVE AWARD PLAN This circular/prospectus (this “Circular/Prospectus”) is being furnished to you as a

As filed with the Securities and Exchange Commission on December 5, 2025

As filed with the Securities and Exchange Commission on December 5, 2025 Registration No.

Oncolytics Biotech Inc. 2026 Incentive Award Plan RESTRICTED STOCK Unit Grant Notice

Exhibit 10.14 Oncolytics Biotech Inc. 2026 Incentive Award Plan RESTRICTED STOCK Unit Grant Notice Capitalized terms not specifically defined in this Restricted Stock Unit Grant Notice (the “Grant Notice”) have the meanings given to them in the 2026 Incentive Award Plan (as amended and/or restated from time to time, the “Plan”) of Oncolytics Biotech Inc. (the “Company”). The Company has granted to

ONCOLYTICS BIOTECH INC. 2026 Incentive Award Plan STOCK OPTION GRANT NOTICE

Exhibit 10.13 ONCOLYTICS BIOTECH INC. 2026 Incentive Award Plan STOCK OPTION GRANT NOTICE Capitalized terms not specifically defined in this Stock Option Grant Notice (the “Grant Notice”) have the meanings given to them in the 2026 Incentive Award Plan (as amended and/or restated from time to time, the “Plan”) of Oncolytics Biotech Inc. (the “Company”). The Company has granted to the participant l

RESOLUTIONS - VOTING RECOMMENDATIONS ARE INDICATED BY HIGHLIGHTED TEXT ABOVE THE BOXES Oncolytics Biotech Inc. (the “Corporation”) Special Meeting January 15, 2026 at 10:00am ET https:// virtual-meetings.tsxtrust.com/1847 password: onc2026 SECURITY C

Exhibit 99.1 Oncolytics Biotech Inc. (the “Corporation”) Special Meeting January 15, 2026 at 10:00am ET https:// virtual-meetings.tsxtrust.com/1847 password: onc2026 (the “Meeting”) Proxy Voting – Guidelines and Conditions 1. THIS PROXY IS SOLICITED BY OR ON BEHALF OF THE MANAGEMENT OF THE CORPORATION. 2. THIS PROXY SHOULD BE READ IN CONJUNCTION WITH THE MEETING MATERIALS PRIOR TO VOTING. 3. If yo

Security Type

Calculation of Filing Fee Tables F-4 ONCOLYTICS BIOTECH INC Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to be Paid 1 Equity Common Stock, par value $0.

Oncolytics Biotech Inc. 2026 Incentive Award Plan RESTRICTED STOCK GRANT NOTICE

Exhibit 10.15 Oncolytics Biotech Inc. 2026 Incentive Award Plan RESTRICTED STOCK GRANT NOTICE Capitalized terms not specifically defined in this Restricted Stock Grant Notice (the “Grant Notice”) have the meanings given to them in the 2026 Incentive Award Plan (as amended and/or restated from time to time, the “Plan”) of Oncolytics Biotech Inc. (the “Company”). The Company has granted to the parti

EMPLOYMENT AGREEMENT

Exhibit 10.5 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (“Agreement”), effective December 4, 2025 (“Effective Date”), is made between Oncolytics Biotech Inc., (“Employer” or the “Company”), and Jared Kelly (“Employee”). Employee and the Company are sometimes referred to herein as the “Parties.” RECITALS A.           Employer is in the business (the “Business”) of developing pharmaceutical prod

ONCOLYTICS BIOTECH INC. Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada, T2R 0C5

ONCOLYTICS BIOTECH INC. Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada, T2R 0C5 VIA EDGAR December 5, 2025 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Jimmy McNamara Re: Oncolytics Biotech Inc. Registration Statement on Form F-4 File No. 333-290954 To the addressee set forth ab

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2025 Commission File Number 001-38512 Oncolytics Bi

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) 4350 Executive Drive, Suite 325 San Diego, CA 92121 (Address of principal executive offices

Oncolytics Biotech® Provides Update on Special Meeting of Shareholders

Oncolytics Biotech® Provides Update on Special Meeting of Shareholders SAN DIEGO, CA, November 20, 2025 – Oncolytics Biotech® Inc.

Oncolytics Biotech® Aligns with FDA on Pivotal Study Design for Pelareorep in First-Line Pancreatic Cancer Company to launch only current registration trial with an immunotherapy in first-line pancreatic cancer in first half of 2026 Trial design allo

Oncolytics Biotech® Aligns with FDA on Pivotal Study Design for Pelareorep in First-Line Pancreatic Cancer Company to launch only current registration trial with an immunotherapy in first-line pancreatic cancer in first half of 2026 Trial design allows flexibility to include an experimental arm with checkpoint inhibitor combination SAN DIEGO, CA, November 19, 2025 – Oncolytics Biotech® Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2025 Commission File Number 001-38512 Oncolytics Bi

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) 4350 Executive Drive, Suite 325 San Diego, CA 92121 (Address of principal executive offices

ONCOLYTICS BIOTECH INC. CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (in thousands of Canadian dollars, except share amounts) As at September 30, 2025 December 31, 2024 Assets Current assets Cash and cash equivalents (note 4) $ 12,

Condensed Interim Consolidated Financial Statements (unaudited) Oncolytics Biotech® Inc.

FORM 52‑109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE

FORM 52‑109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Kirk Look, CFO of Oncolytics Biotech Inc.

MANAGEMENT'S DISCUSSION & ANALYSIS September 30, 2025

MANAGEMENT'S DISCUSSION & ANALYSIS September 30, 2025 November 12, 2025 MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This discussion and analysis should be read in conjunction with our unaudited condensed interim consolidated financial statements and notes thereto as at and for the three and nine months ended September 30, 2025, and should also be read in conjunction with the audited consolidated financial statements and Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") contained in our annual report for the year ended December 31, 2024.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2025 Commission File Number 001-38512 Oncolytics Bi

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant’s name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal execut

FORM 52‑109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE

FORM 52‑109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Jared Kelly, CEO of Oncolytics Biotech Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2025 Commission File Number 001-38512 Oncolytics Bi

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) 4350 Executive Drive, Suite 325 San Diego, CA 92121 (Address of principal executive offices

Oncolytics Biotech® Establishes Gastrointestinal Tumor Scientific Advisory Board to Advance Pelareorep as a Platform Immunotherapy Initial members include Dr. Sanjay Goel (Rutgers), Dr. Deva Mahalingam (Northwestern), and Dr. Dirk Arnold (GOBLET stud

Oncolytics Biotech® Establishes Gastrointestinal Tumor Scientific Advisory Board to Advance Pelareorep as a Platform Immunotherapy Initial members include Dr.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2025 Commission File Number 001-38512 Oncolytics Bio

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) 4350 Executive Drive, Suite 325 San Diego, CA 92121 (Address of principal executive offices)

Oncolytics Biotech® Reports Updated Anal Cancer Data Showing Objective Response Rate More Than Double the Current Standard of Care Pelareorep plus atezolizumab achieves 30% ORR in second-line or later (≥2L) squamous cell anal carcinoma (SCAC) relativ

Oncolytics Biotech® Reports Updated Anal Cancer Data Showing Objective Response Rate More Than Double the Current Standard of Care Pelareorep plus atezolizumab achieves 30% ORR in second-line or later (≥2L) squamous cell anal carcinoma (SCAC) relative to 13.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2025 Commission File Number 001-38512 Oncolytics Bio

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) 4350 Executive Drive, Suite 325 San Diego, CA 92121 (Address of principal executive offices)

Security Type

Calculation of Filing Fee Tables F-4 ONCOLYTICS BIOTECH INC Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to be Paid 1 Equity Common Stock, par value $0.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2025 Commission File Number 001-38512 Oncolytics Bio

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executi

Oncolytics Biotech® Files Circular/Prospectus for Special Meeting of Shareholders To Change Jurisdiction of Incorporation to Nevada

Oncolytics Biotech® Files Circular/Prospectus for Special Meeting of Shareholders To Change Jurisdiction of Incorporation to Nevada SAN DIEGO, CA, October 20, 2025 – Oncolytics Biotech® Inc.

ONCOLYTICS BIOTECH INC. UP TO $50,000,000 OF COMMON SHARES (NO PAR VALUE PER SHARE) AT-THE-MARKET SALES AGREEMENT

Exhibit 1.1 ONCOLYTICS BIOTECH INC. UP TO $50,000,000 OF COMMON SHARES (NO PAR VALUE PER SHARE) AT-THE-MARKET SALES AGREEMENT October 17, 2025 BTIG, LLC 65 East 55th Street New York, New York 10022 Ladies and Gentlemen: Oncolytics Biotech Inc., a company incorporated under the Business Corporations Act (Alberta) (the “Company”), confirms its agreement (this “Agreement”) with BTIG, LLC (“BTIG” and,

As filed with the Securities and Exchange Commission on October 17, 2025

As filed with the Securities and Exchange Commission on October 17, 2025 Registration No.

$50,000,000 Common Shares

Filed Pursuant to Rule 424(b)(5) Registration No. 333-289819 PROSPECTUS SUPPLEMENT (to Prospectus dated August 29, 2025) $50,000,000 Common Shares We have entered into an At-the-Market Sales Agreement (the “Sales Agreement”) with BTIG, LLC (the “Agent”) relating to our common shares offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of the Sales Agr

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2025 Commission File Number 001-38512 Oncolytics Bio

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant’s name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executi

2 Forward-Looking Statements Overview Neither the Securities and Exchange Commission nor any state or foreign securities commission or regulatory authority has passed upon the adequacy or accuracy of this presentation. Any representation to the contr

PELAREOREP a transformative dsRNA immunotherapy platform for gastrointestinal tumors October 2025 Oncolytics Biotech Exhibit 99.

Oncolytics Biotech® Announces Update for Potential First-Line Pancreatic Cancer Registration Study

Oncolytics Biotech® Announces Update for Potential First-Line Pancreatic Cancer Registration Study SAN DIEGO, CA, September 29, 2025 – Oncolytics Biotech® Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2025 Commission File Number 001-38512 Oncolytics B

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal execu

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2025 Commission File Number 001-38512 Oncolytics B

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal execu

Oncolytics Biotech® Provides Update on GOBLET Study Progress and U.S. Site Expansion

Oncolytics Biotech® Provides Update on GOBLET Study Progress and U.S. Site Expansion SAN DIEGO, CA, September 16, 2025 – Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced updates on enrollment progress, U.S. site expansion, and expected data readouts from the ongoing GOBLET trial evaluating pelareo

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2025 Commission File Number 001-38512 Oncolytics B

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal execu

Oncolytics Biotech® Highlights Strong Efficacy and Translational Data in Metastatic Colorectal Cancer; Will Advance Regulatory Pathway Discussions In KRAS mutant 2L mCRC, pelareorep delivers prolonged survival benefit with a median PFS and median OS

Oncolytics Biotech® Highlights Strong Efficacy and Translational Data in Metastatic Colorectal Cancer; Will Advance Regulatory Pathway Discussions In KRAS mutant 2L mCRC, pelareorep delivers prolonged survival benefit with a median PFS and median OS approximately 2.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2025 Commission File Number 001-38512 Oncolytics B

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal execu

Oncolytics Biotech® Provides Updated Clinical Safety Data for Pelareorep, Including Across Multiple Gastrointestinal Tumors Data continue to demonstrate a favorable safety profile for pelareorep across multiple indications and in combination with mul

Oncolytics Biotech® Provides Updated Clinical Safety Data for Pelareorep, Including Across Multiple Gastrointestinal Tumors Data continue to demonstrate a favorable safety profile for pelareorep across multiple indications and in combination with multiple treatments Updated clinical data now account for over 300 gastrointestinal cancer patients, including patients from the GOBLET study, demonstrating pelareorep’s potential as a platform therapy Intravenously administered pelareorep continues to show clinical benefit SAN DIEGO, CA, September 2, 2025 – Oncolytics Biotech® Inc.

EFFECT

X0101 EFFECT 33 LIVE 2025-08-29 16:00:00 F-3 0001129928 ONCOLYTICS BIOTECH INC 333-289819

Oncolytics Biotech® Announces Upcoming Investor Conferences in September

Oncolytics Biotech® Announces Upcoming Investor Conferences in September SAN DIEGO, CA, August 28, 2025 - Oncolytics Biotech® Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2025 Commission File Number 001-38512 Oncolytics Biot

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executiv

LETTER

August 27, 2025 Jared Kelly Chief Executive Officer Oncolytics Biotech Inc. 4350 Executive Drive, Suite 325 San Diego, CA 92121 Re: Oncolytics Biotech Inc. Registration Statement on Form F-3 Filed August 22, 2025 File No. 333-289819 Dear Jared Kelly: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests

ONCOLYTICS BIOTECH INC. Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada, T2R 0C5

ONCOLYTICS BIOTECH INC. Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada, T2R 0C5 VIA EDGAR August 27, 2025 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Tyler Howes Re: Oncolytics Biotech Inc. Registration Statement on Form F-3 File No. 333-289819 To the addressee set forth above:

Security Type

Calculation of Filing Fee Tables F-3 ONCOLYTICS BIOTECH INC Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Newly Registered Securities Equity Common Shares 457(o) Other Subscription Receipts 457(o) Other Warrants 457(o) Other Units 457(o) Fees to be Paid 1 Unallocated (Universal) Shelf 457(o) $ 150,000,000.

As filed with the U.S. Securities and Exchange Commission on August 22, 2025.

As filed with the U.S. Securities and Exchange Commission on August 22, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Oncolytics Biotech Inc. (Exact name of registrant as specified in its charter) Alberta (State or other jurisdiction of incorporation or organization) 26-3847449 (I

Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders

Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders SAN DIEGO, CA, August 11, 2025 - Oncolytics Biotech® Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2025 Commission File Number 001-38512 Oncolytics Biot

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executiv

FORM 52‑109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE

FORM 52‑109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Jared Kelly, CEO of Oncolytics Biotech Inc.

FORM 52‑109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE

FORM 52‑109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Kirk Look, CFO of Oncolytics Biotech Inc.

ONCOLYTICS BIOTECH INC. CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (in thousands of Canadian dollars, except share amounts) As at June 30, 2025 December 31, 2024 Assets Current assets Cash and cash equivalents (note 4) $ 14,626 $

Condensed Interim Consolidated Financial Statements (unaudited) Oncolytics Biotech® Inc.

Oncolytics Biotech® Announces Voluntary Delisting from the Toronto Stock Exchange

Oncolytics Biotech® Announces Voluntary Delisting from the Toronto Stock Exchange SAN DIEGO, CA, August 8, 2025 – Oncolytics Biotech® Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2025 Commission File Number 000-38512 Oncolytics Biot

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2025 Commission File Number 000-38512 Oncolytics Biotech Inc. (Translation of registrant’s name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executiv

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2025 Commission File Number 001-38512 Oncolytics Biot

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executiv

Oncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep Key opinion leader event and pancreatic cancer clinical data validate decision to engage with regulators on plans for a registration-enabli

Oncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep Key opinion leader event and pancreatic cancer clinical data validate decision to engage with regulators on plans for a registration-enabling study New members of the management team bring expertise in progressing clinical programs and executing successful biotech transactions Translational data further elucidate pelareorep’s mechanism of action and ability to prime the tumor microenvironment for treatment Commitment to limiting dilution evidenced by termination of At-the-Market and Equity Line of Credit facilities SAN DIEGO, CA, August 8, 2025 – Oncolytics Biotech® Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2025 Commission File Number 001-38512 Oncolytics Biot

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant’s name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executiv

MANAGEMENT'S DISCUSSION & ANALYSIS June 30, 2025

MANAGEMENT'S DISCUSSION & ANALYSIS June 30, 2025 August 7, 2025 MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This discussion and analysis should be read in conjunction with our unaudited condensed interim consolidated financial statements and notes thereto as at and for the three and six months ended June 30, 2025, and should also be read in conjunction with the audited consolidated financial statements and Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") contained in our annual report for the year ended December 31, 2024.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2025 Commission File Number 001-38512 Oncolytics Biot

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executiv

Oncolytics Biotech® Announces Upcoming Annual General Meeting and Second Quarter Financial Results The management team will provide a brief corporate update after the formal portion of the shareholder meeting

Oncolytics Biotech® Announces Upcoming Annual General Meeting and Second Quarter Financial Results The management team will provide a brief corporate update after the formal portion of the shareholder meeting SAN DIEGO, CA and CALGARY, AB, August 5, 2025 - Oncolytics Biotech® Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2025 Commission File Number 001-38512 Oncolytics Biot

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executiv

Oncolytics Biotech® to Engage FDA for Potential Registration-Enabled Study in First-Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-End Clear regulatory path and strong survival data in first-line metastatic pancreatic ductal aden

Oncolytics Biotech® to Engage FDA for Potential Registration-Enabled Study in First-Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-End Clear regulatory path and strong survival data in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC) support accelerated strategy to drive shareholder value and partnership opportunities SAN DIEGO, CA and CALGARY, AB, July 29, 2025 – Oncolytics Biotech® Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2025 Commission File Number 001-38512 Oncolytics Biotec

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executive

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2025 Commission File Number 001-38512 Oncolytics Biotec

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executive

Key Opinion Leader Event Highlights Pelareorep’s Compelling Pancreatic and Gastrointestinal Data And Future Potential

Key Opinion Leader Event Highlights Pelareorep’s Compelling Pancreatic and Gastrointestinal Data And Future Potential SAN DIEGO, CA and CALGARY, AB, July 23, 2025 – Oncolytics Biotech® Inc.

Oncolytics Biotech® Regains Compliance with Nasdaq Trading Rules

Oncolytics Biotech® Regains Compliance with Nasdaq Trading Rules SAN DIEGO, CA and CALGARY, AB, July 22, 2025 – Oncolytics Biotech® Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2025 Commission File Number 001-38512 Oncolytics Biotec

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executive

Oncolytics Biotech® Presents Aggregated Translational Data Providing Evidence of Pelareorep’s Effectiveness Across Multiple Tumor Types Integrated biomarker analyses confirm viral replication, interferon signaling, and a surge in tumor-infiltrating l

Oncolytics Biotech® Presents Aggregated Translational Data Providing Evidence of Pelareorep’s Effectiveness Across Multiple Tumor Types Integrated biomarker analyses confirm viral replication, interferon signaling, and a surge in tumor-infiltrating lymphocytes after pelareorep treatment Cross-study data show pelareorep increases PD-L1 expression and boosts cytotoxic T-cell activity, priming resistant tumors for checkpoint inhibitors Results reinforce pelareorep’s ability to turn cold tumors hot, paving the way for registration-enabling trials SAN DIEGO, CA and CALGARY, AB, July 16, 2025 – Oncolytics Biotech® Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2025 Commission File Number 001-38512 Oncolytics Biotec

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executive

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2025 Commission File Number 001-38512 Oncolytics Biotec

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executive

Oncolytics Biotech® to Host Key Opinion Leader Discussion Focusing on Pancreatic and Gastrointestinal Cancers KOL webinar to take place on July 22, 2025, at 1:00 p.m. ET

Oncolytics Biotech® to Host Key Opinion Leader Discussion Focusing on Pancreatic and Gastrointestinal Cancers KOL webinar to take place on July 22, 2025, at 1:00 p.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2025 Commission File Number 001-38512 Oncolytics Biotec

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executive

Oncolytics Biotech® Highlights Transformative Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-Enabling Studies Comparison with multiple landmark first-line metastatic pancreatic ductal adenocarcinoma studies substantiates s

Oncolytics Biotech® Highlights Transformative Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-Enabling Studies Comparison with multiple landmark first-line metastatic pancreatic ductal adenocarcinoma studies substantiates strong two-year survival benefit of 21.

Oncolytics Biotech Inc. (the “Corporation”) Annual General Meeting August 8, 2025 at 10:00 a.m. ET via live audio webcast at https://virtual-meetings.tsxtrust.com/1824 password: onc2025 (the “Meeting”) Proxy Voting – Guidelines and Conditions 1. THIS

Oncolytics Biotech Inc. (the “Corporation”) Annual General Meeting August 8, 2025 at 10:00 a.m. ET via live audio webcast at https://virtual-meetings.tsxtrust.com/1824 password: onc2025 (the “Meeting”) Proxy Voting – Guidelines and Conditions 1. THIS PROXY IS SOLICITED BY OR ON BEHALF OF THE MANAGEMENT OF THE CORPORATION. 2. THIS PROXY SHOULD BE READ IN CONJUNCTION WITH THE MEETING MATERIALS PRIOR

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2025 Commission File Number 001-38512 Oncolytics Biotec

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant’s name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executive

NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON AUGUST 8, 2025 - AND - MANAGEMENT INFORMATION CIRCULAR June 18, 2025

NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON AUGUST 8, 2025 - AND - MANAGEMENT INFORMATION CIRCULAR June 18, 2025 June 18, 2025 Dear Shareholder: Important Notice regarding Participation in the Annual General Meeting of Shareholders on August 8, 2025 Oncolytics Biotech Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2025 Commission File Number 001-38512 Oncolytics Biotec

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executive

Oncolytics Biotech® Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy

Oncolytics Biotech® Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy SAN DIEGO, CA and CALGARY, AB, June 30, 2025 – Oncolytics Biotech® Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2025 Commission File Number 001-38512 Oncolytics Biotec

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executive

Oncolytics Biotech® Names New CEO to Accelerate Momentum in Immunotherapy Programs

Oncolytics Biotech® Names New CEO to Accelerate Momentum in Immunotherapy Programs SAN DIEGO, CA and CALGARY, AB, June 11, 2025 – Oncolytics Biotech® Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2025 Commission File Number 001-38512 Oncolytics Biotech

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executive o

Oncolytics Biotech® to Present New Clinical Trial Data at ASCO Showing Pelareorep’s Unique Immune Activation Capabilities Pelareorep initiates a pro-inflammatory tumor microenvironment (TME) and induces innate and adaptive immune responses New analys

Oncolytics Biotech® to Present New Clinical Trial Data at ASCO Showing Pelareorep’s Unique Immune Activation Capabilities Pelareorep initiates a pro-inflammatory tumor microenvironment (TME) and induces innate and adaptive immune responses New analyses confirm that pelareorep primes the TME to allow circulating tumor-infiltrating lymphocytes (TILs) in the blood to attack tumors Pre-existing TIL clones in plasma may correlate positively with tumor shrinkage in pancreatic cancer SAN DIEGO, CA and CALGARY, AB, May 23, 2025 – Oncolytics Biotech® Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2025 Commission File Number 001-38512 Oncolytics Biotech

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant’s name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executive o

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2025 Commission File Number 001-38512 Oncolytics Biotech

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executive o

FORM 52‑109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE

FORM 52‑109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Wayne Pisano, Interim CEO of Oncolytics Biotech Inc.

ONCOLYTICS BIOTECH INC. CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (in thousands of Canadian dollars, except share amounts) As at March 31, 2025 December 31, 2024 Assets Current assets Cash and cash equivalents (note 4) $ 15,303

Condensed Interim Consolidated Financial Statements (unaudited) Oncolytics Biotech® Inc.

FORM 52‑109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE

FORM 52‑109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Kirk Look, CFO of Oncolytics Biotech Inc.

Oncolytics Biotech® Reports First Quarter Financial Results and Highlights Clinical Momentum American Society of Clinical Oncology (ASCO) GI Symposium data underscores pelareorep’s clinical benefit in anal and pancreatic cancers Pelareorep featured i

Oncolytics Biotech® Reports First Quarter Financial Results and Highlights Clinical Momentum American Society of Clinical Oncology (ASCO) GI Symposium data underscores pelareorep’s clinical benefit in anal and pancreatic cancers Pelareorep featured in Key Opinion Leader event on oncolytic immunotherapies in breast and pancreatic cancers Poster on pelareorep’s stimulation of adaptive and innate immunity to be shared at ASCO Annual Meeting Conference call and webcast today at 4:30 p.

MANAGEMENT'S DISCUSSION & ANALYSIS March 31, 2025

MANAGEMENT'S DISCUSSION & ANALYSIS March 31, 2025 May 14, 2025 MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This discussion and analysis should be read in conjunction with our unaudited condensed interim consolidated financial statements and notes thereto as at and for the three months ended March 31, 2025, and should also be read in conjunction with the audited consolidated financial statements and Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") contained in our annual report for the year ended December 31, 2024.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2025 Commission File Number 001-38512 Oncolytics Biotech

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executive o

Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights Conference call and webcast to take place on Wednesday, May 14, 2025, at 4:30 p.m. ET

Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights Conference call and webcast to take place on Wednesday, May 14, 2025, at 4:30 p.

Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep’s Tumor-Fighting Mechanism of Action ASCO data expected to highlight how pelareorep activates immune responses in pancreatic cancer patients Ongoing updates su

Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep’s Tumor-Fighting Mechanism of Action ASCO data expected to highlight how pelareorep activates immune responses in pancreatic cancer patients Ongoing updates support potential of pelareorep combination therapies in one of the deadliest and hardest-to-treat cancers SAN DIEGO, CA and CALGARY, AB, April 24, 2025 – Oncolytics Biotech® Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2025 Commission File Number 001-38512 Oncolytics Biote

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executive

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2025 Commission File Number 001-38512 Oncolytics Biote

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executive

Oncolytics Biotech® Funds Pelareorep’s Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital

Oncolytics Biotech® Funds Pelareorep’s Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital SAN DIEGO, CA and CALGARY, AB, April 10, 2025 – Oncolytics Biotech® Inc.

PURCHASE AGREEMENT

Exhibit 99.1 PURCHASE AGREEMENT PURCHASE AGREEMENT (this “Agreement”), dated as of April 10, 2025 (the “Execution Date”), is entered into by and between ONCOLYTICS BIOTECH INC., a company incorporated under the Business Corporations Act (Alberta) (the “Company”), and ALUMNI CAPITAL LP, a Delaware limited partnership (the “Investor”). RECITALS WHEREAS, subject to the terms and conditions set forth

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2025 Commission File Number 000-38512 Oncolytics Biote

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2025 Commission File Number 000-38512 Oncolytics Biotech Inc. (Translation of registrant’s name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executive

Common Shares

Filed pursuant to General Instruction II.L of Form F-10 File No. 333-281009 PROSPECTUS SUPPLEMENT (To Base Shelf Prospectus dated July 19, 2024) US$20,800,000 Common Shares This prospectus supplement (the “Prospectus Supplement”) of Oncolytics Biotech Inc. (“Oncolytics” or the “Corporation”), together with the accompanying short form base shelf prospectus dated July 19, 2024 (the “Prospectus”), qu

Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers

Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers SAN DIEGO, CA and CALGARY, AB, April 10, 2025 – Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, was discussed by field-leading key opinion leaders (KOLs) dur

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2025 Commission File Number 001-38512 Oncolytics Biote

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executive

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

EXHIBIT 15.2 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the following Registration Statements: 1.Form S-8 nos. 333-171625, 333-205708 and 333-279926 2.Form F-10 no. 333-281009 of Oncolytics Biotech Inc. (the “Company”) of our reports dated March 6, 2025, with respect to the consolidated statements of financial position as at December 31

DESCRIPTION OF RIGHTS OF SECURITIES REGISTERED UNDER SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934

EXHIBIT 2.1 DESCRIPTION OF RIGHTS OF SECURITIES REGISTERED UNDER SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Our authorized capital consists of an unlimited number of Common Shares. The following is a summary of the provisions attached to our Common Shares: The holders of our Common Shares are entitled to one vote per share at meetings of shareholders, to receive such dividends as declared b

LIST OF SUBSIDIARIES Name Jurisdiction Oncolytics Biotech (Barbados) Inc. Barbados Oncolytics Biotech (US) Inc. Delaware

EXHIBIT 8.0 LIST OF SUBSIDIARIES 2024 Name Jurisdiction Oncolytics Biotech (Barbados) Inc. Barbados Oncolytics Biotech (US) Inc. Delaware

Date: March 7, 2025 /s/Kirk Look Kirk Look, CA Chief Financial Officer Principal Accounting and Financial Officer

EXHIBIT 12.2 CERTIFICATION I, Kirk Look, certify that: 1.I have reviewed this annual report on Form 20-F of Oncolytics Biotech Inc.; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to t

CERTIFICATION PURSUANT TO 18 U.S.C. §1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

EXHIBIT 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. §1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the annual report of Oncolytics Biotech Inc. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2024, as filed with the Securities and Exchange Commission on the date here of (the “Report”), I, Wayne Pisano, Interim Chief Executive Officer

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2025 Commission File Number 001-38512 Oncolytics Biote

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executive

Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024 BRACELET-1 results in HR+/HER2- metastatic breast cancer surpass expectations, providing meaningful data for a registration-enabling study Data from GOBLET in pancr

Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024 BRACELET-1 results in HR+/HER2- metastatic breast cancer surpass expectations, providing meaningful data for a registration-enabling study Data from GOBLET in pancreatic and anal carcinoma support continued development of pelareorep in these indications, with combination studies ongoing Cash position of $15.

MANAGEMENT'S DISCUSSION & ANALYSIS

MANAGEMENT'S DISCUSSION & ANALYSIS 2024 March 6, 2025 MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS BASIS OF PRESENTATION Our Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") should be read in conjunction with our audited consolidated financial statements and notes thereto as at and for the year ended December 31, 2024, which have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB").

Date: March 7, 2025 /s/Wayne Pisano Wayne Pisano Interim Chief Executive Officer Interim Principal Executive Officer

EXHIBIT 12.1 CERTIFICATION I, Wayne Pisano, certify that: 1.I have reviewed this annual report on Form 20-F of Oncolytics Biotech Inc.; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For fiscal year ended December 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 19

CERTIFICATION PURSUANT TO 18 U.S.C. §1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

EXHIBIT 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. §1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the annual report of Oncolytics Biotech Inc. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2024, as filed with the Securities and Exchange Commission on the date here of (the “Report”), I, Kirk Look, Chief Financial Officer of the Com

Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights Conference call and webcast to take place on Friday, March 7, 2025, at 8:30 a.m. ET

Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights Conference call and webcast to take place on Friday, March 7, 2025, at 8:30 a.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2025 Commission File Number 001-38512 Oncolytics Bi

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal execut

Oncolytics Biotech® Advances Key Pancreatic and Anal Cancer Trials, Strengthening Pipeline in 2025 Regulatory progress in pancreatic cancer and recent clinical data presentations in two hard-to-treat GI cancers, coupled with strong efficacy signals i

Oncolytics Biotech® Advances Key Pancreatic and Anal Cancer Trials, Strengthening Pipeline in 2025 Regulatory progress in pancreatic cancer and recent clinical data presentations in two hard-to-treat GI cancers, coupled with strong efficacy signals in breast cancer, highlight pelareorep’s potential impact across a range of tumors SAN DIEGO, CA and CALGARY, AB, February 19, 2025 – Oncolytics Biotech® Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2025 Commission File Number 001-38512 Oncolytics Bi

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal execut

Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer Recent clinical data presentations in these two hard-to-treat GI cancers, coupled with strong efficacy signals i

Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer Recent clinical data presentations in these two hard-to-treat GI cancers, coupled with strong efficacy signals in breast cancer, demonstrate the potential of pelareorep across very different tumor types SAN DIEGO, CA and CALGARY, AB, February 18, 2025 – Oncolytics Biotech® Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2025 Commission File Number 001-38512 Oncolytics Bi

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal execut

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2025 Commission File Number 001-38512 Oncolytics Bi

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal execut

Oncolytics Biotech® Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

Oncolytics Biotech® Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency SAN DIEGO, CA and CALGARY, AB, February 14, 2025 – Oncolytics Biotech® Inc.

ONCY / Oncolytics Biotech Inc. / Anson Funds Management LP - EX-99.1 /=;=Q%PWNR_%Y; M3U\^,0*W H=&%.FF<2WQ)!#?%"_$VS6X&TT,&FKRR3&2T2BG$D91WR$9#,@" M37$X?)FI+ \[.?EDN=R722^7=X^7>7C8/:@:J3"-C7M*#V/U+'T'CV_; ;[0 MKHZ1(W-]=.Q0[LW,;?)=*ETJ:Y76^1[R[?(I KYU/@%\,6G1WLFRR

begin 644 ck0001669811-ex991.pdf M)5!$1BTQ+C<*"C0@,"!O8FH**$ED96YT:71Y*0IE;F1O8FH*-2 P(&]B:@HH M061O8F4I"F5N9&]B:@HX(# @;V)J"CP\"B]&:6QT97(@+T9L871E1&5C;V1E M"B],96YG=&@@-S,U-34*+TQE;F=T:#$@,S4R.3(T"B]4>7!E("]3=')E86T* M/CX*<['T)8%3%?]WWGM[W[EV-YMD=[/9S;%)=G,?!+(Y.<(1 M(4""1!)N$"2<%2L"7FA0H=ZV5K"M1ZNMFP0TH#]%B[<('A5M55#Q+I6V7E62 M7]G-B0DH;]*(+QWS>SF?FS4K\* M0+!@>E-MQ=BZAM?6?X#[WXKK^5,JQ]6/=\V'&#*0

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2025 Commission File Number 001-38512 Oncolytics Bi

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal execut

Oncolytics Biotech® Announces Matt Coffey, Ph.D. Will Not Return to CEO Role Following Medical Leave of Absence Search for Chief Executive Officer to commence immediately

Oncolytics Biotech® Announces Matt Coffey, Ph.D. Will Not Return to CEO Role Following Medical Leave of Absence Search for Chief Executive Officer to commence immediately SAN DIEGO, CA and CALGARY, AB, February 7, 2025 – Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that Matt Coffey, Ph.D., President

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January 2025 Commission File Number 001-38512 Oncolytics Bio

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executi

Oncolytics Biotech® to Present Compelling New Efficacy and Safety Data in Anal and Pancreatic Cancers at 2025 ASCO GI Symposium Pelareorep combination therapy shows continued meaningful improvement over checkpoint inhibitors alone in anal cancer pati

Oncolytics Biotech® to Present Compelling New Efficacy and Safety Data in Anal and Pancreatic Cancers at 2025 ASCO GI Symposium Pelareorep combination therapy shows continued meaningful improvement over checkpoint inhibitors alone in anal cancer patients Pelareorep-based therapy demonstrates strong safety profile with new chemotherapy regimen in pancreatic cancer patients SAN DIEGO, CA and CALGARY, AB, January 22, 2025 – Oncolytics Biotech® Inc.

Regulatory Approval Clears Path for Oncolytics Biotech® to Advance Promising Pancreatic Cancer Treatment, Following a Review of Safety Data New pancreatic cancer cohort moves forward with full enrollment of 30 patients in Stage 1

Regulatory Approval Clears Path for Oncolytics Biotech® to Advance Promising Pancreatic Cancer Treatment, Following a Review of Safety Data New pancreatic cancer cohort moves forward with full enrollment of 30 patients in Stage 1 SAN DIEGO, CA and CALGARY, AB, January 15, 2025 – Oncolytics Biotech® Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January 2025 Commission File Number 001-38512 Oncolytics Bio

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January 2025 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executi

Oncolytics Biotech® Highlights 2024 Achievements and Prepares for an Influential 2025 with Promising Breast and GI Cancer Data Promising BRACELET-1 results in HR+/HER2- metastatic breast cancer lay the foundation for potential registration-enabling s

Oncolytics Biotech® Highlights 2024 Achievements and Prepares for an Influential 2025 with Promising Breast and GI Cancer Data Promising BRACELET-1 results in HR+/HER2- metastatic breast cancer lay the foundation for potential registration-enabling study and accelerated approval Advancing gastrointestinal cancer pipeline underscores potential for additional registration-enabling studies SAN DIEGO, CA and CALGARY, AB, December 23, 2024 - Oncolytics Biotech® Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2024 Commission File Number 001-38512 Oncolytics Bi

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2024 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal execut

Oncolytics Biotech® to Present Promising Pelareorep Data in Pancreatic and Anal Cancers at ASCO GI Symposium

Oncolytics Biotech® to Present Promising Pelareorep Data in Pancreatic and Anal Cancers at ASCO GI Symposium SAN DIEGO, CA and CALGARY, AB, December 18, 2024 – Oncolytics Biotech® Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2024 Commission File Number 001-38512 Oncolytics Bi

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2024 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal execut

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2024 Commission File Number 001-38512 Oncolytics Bi

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2024 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal execut

Oncolytics Biotech® Reports Completion of Initial Safety Phase Enrollment for GOBLET Trial’s New Pancreatic Cancer Cohort Early safety and tolerability results from six randomized patients support continued enrollment of pelareorep combined with modi

Oncolytics Biotech® Reports Completion of Initial Safety Phase Enrollment for GOBLET Trial’s New Pancreatic Cancer Cohort Early safety and tolerability results from six randomized patients support continued enrollment of pelareorep combined with modified FOLFIRINOX, with or without atezolizumab The study will begin with 30 patients, with an option to expand to an additional 34 participants SAN DIEGO, CA and CALGARY, AB, December 3, 2024 - Oncolytics Biotech® Inc.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2024 Commission File Number 001-38512 Oncolytics Bi

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2024 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal execut

FORM 52‑109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE

FORM 52‑109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Kirk Look, CFO of Oncolytics Biotech Inc.

MANAGEMENT'S DISCUSSION & ANALYSIS September 30, 2024

MANAGEMENT'S DISCUSSION & ANALYSIS September 30, 2024 November 9, 2024 MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This discussion and analysis should be read in conjunction with our unaudited condensed interim consolidated financial statements and notes thereto as at and for the three and nine months ended September 30, 2024, and should also be read in conjunction with the audited consolidated financial statements and Management's Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) contained in our annual report for the year ended December 31, 2023.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2024 Commission File Number 001-38512 Oncolytics Bi

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2024 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal execut

FORM 52‑109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE

FORM 52‑109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Wayne Pisano, Interim CEO of Oncolytics Biotech Inc.

ONCOLYTICS BIOTECH INC. CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (in thousands of Canadian dollars, except share amounts) As at September 30, 2024 December 31, 2023 Assets Current assets Cash and cash equivalents (note 4) $ 19,

Condensed Interim Consolidated Financial Statements (unaudited) Oncolytics Biotech® Inc.

Oncolytics Biotech® Reports Third Quarter 2024 Financial Results and Operational Highlights BRACELET-1 data showing impressive overall survival benefit in HR+/HER2- metastatic breast cancer affirms pelareorep + paclitaxel combination should be evalua

Oncolytics Biotech® Reports Third Quarter 2024 Financial Results and Operational Highlights BRACELET-1 data showing impressive overall survival benefit in HR+/HER2- metastatic breast cancer affirms pelareorep + paclitaxel combination should be evaluated in a registrational study Upcoming GOBLET milestones include updated efficacy data from anal cancer cohort and safety run-in data from the modified FOLFIRINOX pancreatic cancer cohort Cash position of $19.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2024 Commission File Number 001-38512 Oncolytics Bi

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2024 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant’s name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal execut